

SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE

Alberto BORGHETTI - Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive

Arturo CICCULLO - Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma Italia

Gianmaria BALDIN - Mater Olbia Hospital, Olbia, Italy

Stefano RUSCONI - Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy.

Amedeo CAPETTI - Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy.

Gaetana STERRANTINO - Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy

William GENNARI - Azienda Ospedaliero Universitaria di Modena Laboratorio di Microbiologia e Virologia, Modena, Italy

Cristina MUSSINI - Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy

Vanni BORGHI - Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, Italy

Simona DI GIAMBENEDETTO - Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC Malattie Infettive; Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma Italia

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Corresponding author: Dr. Arturo CICCULLO, Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy. Telephone number: +39 06-30155366. E-mail address: arturo.ciccullo@gmail.com

Dear editor,

After previous evidence from the ASPIRE trial [1], results from TANGO study [2] definitively proved the efficacy of lamivudine (3TC) plus dolutegravir (DTG) as a maintenance strategy. As trials' populations often differ from real-practice settings, we aimed to assess whether these results are reproducible in an unselected HIV-population. An observational longitudinal multicenter research study was conducted. HIV-positive patients with viral suppression (at least one HIV-RNA<50 copies/mL) were followed-up from the start of 3TC+DTG. The cohort was divided into two groups based on compliance or not with the inclusion criteria of TANGO study (absence of HBV-coinfection, of previous virological failure (VF), of a M184V-harboring virus and of previous AIDS-event other than cutaneous Kaposi's sarcoma and nadir CD4 count \leq 200 mm³).

Time to VF (i.e. 2 consecutive HIV-RNA determinations \geq 50 cps/mL or a single HIV-RNA \geq 1000 cps/mL) and to treatment discontinuation (TD, i.e. the interruption of any of the study drugs) in the 2 groups were compared through Kaplan-Meier with log-rank test and Cox-regression model after adjusting for the main clinical and demographic between-groups differences. Changes in immunological parameters were assessed by linear mixed model for repeated measures.

We analyzed 557 patients with a median follow-up time of 22 months: 145 (26.0%) met the TANGO inclusion criteria (TANGO group, TG). They were mostly men (70.4%), of Caucasians ethnicity (92.1%). Characteristics of study groups are summarized in table 1.

One VF over 248 PYFU and 11 VF over 776 PYFU occurred in the TG and non-TG, respectively. The estimated probability of maintaining virological suppression was 99.2% (SD \pm 1.6) at 48, 96 and 144 weeks in the TG, and 98.5% (SD \pm 1.4) at 48 weeks, 97.7 (SD \pm 1.8) at 96 weeks and 95.7% (SD \pm 2.6) at 144 weeks in the non-TG (log-rank p=0.189). After stratifying for the presence of M184V at historical genotype and for previous VF the results did not change (p=0.253 and p=0.186). Moreover, belonging to TG was not predictive of VF (aHR 0.35, 95%CI 0.04-2.84; p=0.327) after adjusting for age, anti-HCV serostatus and HIV duration. No resistance-associated mutations emerged after VF.

Estimated probabilities of remaining on 3TC+DTG were 86.6% (SD±5.9) at week 48 and 79.5% (SD±7.5) at both weeks 96 and 144 in the TG, and 85.8% (SD±3.5), 78.9% (SD±4.3) and 73.9% (SD±5.1) at weeks 48, 96 and 144 in the non-TG (log-rank $p=0.654$), with no significantly-increased hazard of TD for the TG (vs non-TG, aHR 0.97, 95%CI 0.60-1.57, $p=0.894$) after adjusting for confounders. A significant increase in CD4/CD8 ratio (mean change at 96 weeks, +0.05 in TG and +0.07 in non-TG) was observed over time, with no difference between groups.

Previous studies on 3TC+DTG as a switch strategy reported low rate of VF in clinical practice [3,4]. However, some demographic and viro-immunological characteristics seemed to increase the risk of VF during 3TC+DTG [5], possibly limiting the widespread use of this strategy in experienced patients. Overall, our findings from clinical practice are in line with the TANGO study results. However, a higher, albeit not statistically-significant, number of VF was seen in the non-TG: pending results from longer follow-up studies, in our opinion caution should be advised when considering 3TC+DTG for selected patients (e.g., those with previous VF or shorter time of viral suppression).

Acknowledgements

We thank all collaborators of the study: Alessandra Latini, Manuela Colafigli, Luigi Celani, Gabriella d'Ettore (Roma), Andrea Giacometti (Ancona), Filippo Lagi (Firenze), Andrea Giacomelli and Maria Vittoria Cossu (Milano).

Transparency declaration

AB has received non-financial support from Bristol-Myers Squibb and ViiV Healthcare, and personal fees from Gilead Sciences and Janssen. SR received research grants to his Institution from ViiV Healthcare, Bristol-Myers Squibb, Gilead Sciences and Janssen, outside the submitted work; he was also a paid consultant for ViiV Healthcare, Gilead Sciences, Merck Sharp and Dohme, Bristol-Myers Squibb, Mylan, and Janssen. ACa has received a personal grant from Abbvie, Gilead and ViiV. GS has received funds for speaking by Gilead, Merck, Janssen, Abbvie, ViiV. CM has participated in advisory boards, received study grants and/or speaker honoraria from: Abbvie, Gilead, ViiV, Janssen, Angelini, BMS, MSD. SDG was a paid consultant or member of advisory boards for Gilead, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme and Bristol-Myers Squibb. All other authors: none to declare.

References

1. Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. *Clin Infect Dis*. 2018 May 17;66(11):1794-1797.
2. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study [published online ahead of print, 2020 Jan 6]. *Clin Infect Dis*. 2020;ciz1243. doi:10.1093/cid/ciz1243
3. Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. *BMC Infect Dis*. 2017;17(1):215. Published 2017 Mar 16. doi:10.1186/s12879-017-2311-2
4. Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, et al. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. *Medicine (Baltimore)*. 2019;98(32):e16813. doi:10.1097/MD.00000000000016813
5. Borghetti A, Moschese D, Cingolani A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. *HIV Med*. 2019;20(9):624–627. doi:10.1111/hiv.12759

Table 1. Baseline patients' characteristics.

	TANGO group (n=145)	Non-TANGO group (n=412)	P value
Age (Years), Median (IQR)	49 (40-55)	53 (47-58)	<0.001
Male sex, n (%)	111 (76.6)	281 (68.2)	0.058
Ethnicity, n (%):			0.112
- Caucasians	129 (89.0)	384 (93.2)	
- Sub-Saharan	4 (2.8)	14 (3.4)	
- Central-South American	6 (4.1)	6 (1.5)	
- Other/unknown	6 (4.1)	8 (1.9)	
Risk factor for HIV, n (%):			<0.001
- Heterosexual	56 (38.6)	169 (41.0)	
- MSM	37 (25.5)	108 (26.2)	
- IDU	15 (10.4)	86 (20.9)	
- Other/Unknown	37 (25.5)	49 (11.9)	
CDC Stage C, n (%)	20 (13.8)	62 (15.0)	0.854
Anti HCV positive serostatus, n (%)	25 (17.2)	101 (24.5)	0.076
Peak HIV-RNA (log₁₀ copies/mL), median (IQR)	4.95 (4.45-5.35)	4.89 (4.37-5.43)	0.780
Nadir CD4+ cell count (cells/mm³), median (IQR)	278 (140-395)	212 (93-309)	0.001
Non-B HIV subtype, n (%)	5 (3.4)	13 (3.2)	0.875
Years from HIV diagnosis, median (IQR)	9 (5-17)	18 (10-24)	<0.001
Years of cumulative ARVs exposure, median (IQR)	7 (3-12)	13 (8-19)	<0.001
Months of virological suppression, median (IQR)	61.5 (31.5-103.1)	95.4 (51.5-126.9)	<0.001
Time of virological suppression ≤ 6 months (%)	/	13 (3.2)	NA

Baseline CD4+ cell count (cells/mm³), median (IQR)	692 (453-912)	660 (500-876)	0.826
Previous virological failure, n (%)	/	223 (54.1)	NA
Previous ARV regimen, n (%):			<0.001
- 2NRTI + bPI	22 (15.2)	55 (13.3)	
- 2NRTI + NNRTI	90 (62.1)	55 (13.3)	
- 2NRTI + INI	33 (22.7)	57 (13.8)	
- Dual/Monotherapy	0 (0)	220 (53.4)	
- Other	0 (0)	25 (6.2)	
M184V resistance mutation detection at last genotypic resistance test, n (%)	/	45 (10.9)	NA
Reason for starting DTG+3TC, n (%):			<0.001
- Simplification/Proactive switch	49 (33.8)	106 (25.7)	
- Dyslipidemia	5 (3.4)	87 (21.1)	
- Toxicity GI tract	13 (9.0)	31 (7.5)	
- Renal toxicity	13 (9.0)	18 (4.4)	
- Osteopenia/osteoporosis	20 (13.8)	7 (1.7)	
- Other toxicity	10 (6.8)	10 (2.4)	
- Drug-drug interaction	6 (4.1)	30 (7.3)	
- Other/Unknown	29 (20.1)	123 (29.9)	

Notes: IQR, inter-quartile range; MSM, men who have sex with men; IDU, intravenous drug users;

ARV, antiretroviral; (N)NRTI, (non) nucleoside-reverse transcriptase inhibitor; bPI, boosted-protease inhibitor; INI, integrase inhibitor; GI, gastro-intestinal.